
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib) significantly improved hematocrit levels and reduced spleen size, key measures of disease control[2] … Read the full press release